Complete report is available @ http://www.reportsnreports.com/reports/291517-pharmapoint-prophylactic-human-papillomavirus-vaccines-us-drug-forecast-and-market-analysis-to-2022.html . In the US the total number of HPV vaccine doses delivered annually is likely to grow steadily over the next few years, as more males receive vaccination and Merck's nine-valent vaccine V503 becomes available in 2015. US market growth will contribute to global growth in the HPV vaccines sector. There is no indication that coverage rates for adolescent girls will increase dramatically over the forecast period, as they have been relatively stable over the past few years. However, a modest increase will likely be achieved following the introduction of V503, which will be accompanied by a marketing and awareness campaign.

1. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US Drug
Forecast and Market Analysis to 2022
Published: Mar 2014
Single User PDF: US$ 4995
Corporate User PDF: US$ 14985
Order this report by calling
+1 888 391 5441 or Send an email
to sales@reportsandreports.com
with your contact details and
questions if any.
1© ReportsnReports.com / Contact sales@reportsandreports.com

2. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US
Drug Forecast and Market Analysis to 2022
The first prophylactic vaccine for immunization against human papillomavirus (HPV)
became available in 2006. The global HPV vaccines market is now well established, yet
vaccine coverage rates amongst the traditional target population of adolescent girls
remain persistently low. Initially HPV vaccines were developed and marketed solely to
protect against cervical cancer. In recent years the role of HPV in other cancers has been
increasingly recognized which has facilitated a shift towards vaccinating a wider
population, most significant has been the inclusion of males in routine vaccine
recommendations in some countries. The current HPV vaccines market is dominated by
one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix
providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is
set to change the future landscape of the HPV vaccines sector.
In the US the total number of HPV vaccine doses delivered annually is likely to grow
steadily over the next few years, as more males receive vaccination and Merck's nine-
valent vaccine V503 becomes available in 2015. US market growth will contribute to
global growth in the HPV vaccines sector.
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
2© ReportsnReports.com / Contact sales@reportsandreports.com

3. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US
Drug Forecast and Market Analysis to 2022
Scope
Overview of Prophylactic Human Papillomavirus Vaccines including epidemiology,
etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
Detailed information on the key drugs in the US including product description, safety and
efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in the US from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting the US
Prophylactic Human Papillomavirus Vaccines disease market.
Request a sample of this report @
http://www.reportsnreports.com/contacts/requestsample.aspx?name=291517 .
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
3© ReportsnReports.com / Contact sales@reportsandreports.com

4. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US
Drug Forecast and Market Analysis to 2022
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust
return
Stay ahead of the competition by understanding the changing competitive landscape for
Prophylactic Human Papillomavirus Vaccines
Effectively plan your M&A and partnership strategies by identifying drugs with the most
promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug
performance
Obtain sales forecast for drugs from 2012-2022 in the US
Complete report is available @ http://www.reportsnreports.com/reports/291517-
pharmapoint-prophylactic-human-papillomavirus-vaccines-us-drug-forecast-and-
market-analysis-to-2022.html .
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
4© ReportsnReports.com / Contact sales@reportsandreports.com

5. PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US
Drug Forecast and Market Analysis to 2022
Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 13
3.2 Symptoms 15
Buy a copy of this report @
http://www.reportsnreports.com/purchase.aspx?name=291517 .
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
5© ReportsnReports.com / Contact sales@reportsandreports.com